Solid Biosciences (SLDB) Share-based Compensation (2017 - 2026)

Solid Biosciences (SLDB) has 10 years of Share-based Compensation data on file, last reported at $5.2 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 54.21% year-over-year to $5.2 million; the trailing twelve-month figure through Mar 2026 stood at $18.7 million (up 52.87% YoY), and the FY2025 full-year result was $16.9 million, up 60.79% from the prior year.
• Share-based Compensation declined to $5.2 million in Q1 2026, from $6.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $6.5 million in Q4 2025 to a low of -$21.6 million in Q4 2022.
• A 5-year average of $1.4 million and a median of $2.4 million in 2022 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation tumbled 732.18% in 2022 and jumped 107.39% in 2025, its largest moves.
• Tracing SLDB's Share-based Compensation over 5 years: stood at -$21.6 million in 2022, then jumped by 107.53% to $1.6 million in 2023, then jumped by 135.14% to $3.8 million in 2024, then soared by 70.11% to $6.5 million in 2025, then slipped by 20.74% to $5.2 million in 2026.
• Business Quant data shows SLDB's Share-based Compensation at $5.2 million in Q1 2026, $6.5 million in Q4 2025, and $3.9 million in Q3 2025.